

## Lung cancer susceptibility

- polymorphisms in lung cancer patients. *Cancer Res*, 61(4), 1354-7 (2001)
58. S. Benhamou and A. Sarasin: ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review. *Am J Epidemiol*, 161(1), 1-14 (2005)
59. G. Francisco, P. R. Menezes, J. Eluf-Neto and R. Chammas: Arg72Pro TP53 polymorphism and cancer susceptibility: A comprehensive meta-analysis of 302 case-control studies. *Int J Cancer* (2010)
60. Y. Li, L. X. Qiu, X. K. Shen, X. J. Lv, X. P. Qian and Y. Song: A meta-analysis of TP53 codon 72 polymorphism and lung cancer risk: evidence from 15,857 subjects. *Lung Cancer*, 66(1), 15-21 (2009)
61. E. Tsuchiya, R. Furuta, N. Wada, K. Nakagawa, Y. Ishikawa, B. Kawabuchi, Y. Nakamura and H. Sugano: High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs. *J Cancer Res Clin Oncol*, 121(9-10), 577-81 (1995)
62. L. Lin, M. F. Festing, T. R. Devereux, K. A. Crist, S. C. Christiansen, Y. Wang, A. Yang, K. Svenson, B. Paigen, A. M. Malkinson and M. You: Additional evidence that the K-ras protooncogene is a candidate for the major mouse pulmonary adenoma susceptibility (Pas-1) gene. *Exp Lung Res*, 24(4), 481-97 (1998)
63. J. P. Koivunen, J. Kim, J. Lee, A. M. Rogers, J. O. Park, X. Zhao, K. Naoki, I. Okamoto, K. Nakagawa, B. Y. Yeap, M. Meyerson, K. K. Wong, W. G. Richards, D. J. Sugarbaker, B. E. Johnson and P. A. Janne: Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. *Br J Cancer*, 99(2), 245-52 (2008)
64. M. F. Paz, S. Avila, M. F. Fraga, M. Pollan, G. Capella, M. A. Peinado, M. Sanchez-Cespedes, J. G. Herman and M. Esteller: Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. *Cancer Res*, 62(15), 4519-24 (2002)
65. L. Makowski and D. N. Hayes: Role of LKB1 in lung cancer development. *Br J Cancer*, 99(5), 683-8 (2008)
66. J. E. Cropley, D. I. Martin and C. M. Suter: Germline epimutation in humans. *Pharmacogenomics*, 9(12), 1861-8 (2008)
67. D. Miki, M. Kubo, A. Takahashi, K. A. Yoon, J. Kim, G. K. Lee, J. I. Zo, J. S. Lee, N. Hosono, T. Morizono, T. Tsunoda, N. Kamatani, K. Chayama, T. Takahashi, J. Inazawa, Y. Nakamura and Y. Daigo: Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. *Nat Genet*, 42(10), 893-6 (2010)
68. M. Spinola, V. P. Leoni, A. Galvan, E. Korsching, B. Conti, U. Pastorino, F. Ravagnani, A. Columbano, V. Skaug, A. Haugen and T. A. Dragani: Genome-wide single nucleotide polymorphism analysis of lung cancer risk detects the KLF6 gene. *Cancer Lett*, 251(2), 311-6 (2007)
69. C. I. Amos, X. Wu, P. Broderick, I. P. Gorlov, J. Gu, T. Eisen, Q. Dong, Q. Zhang, X. Gu, J. Vijaykrishnan, K. Sullivan, A. Matakidou, Y. Wang, G. Mills, K. Doheny, Y. Y. Tsai, W. V. Chen, S. Shete, M. R. Spitz and R. S. Houlston: Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. *Nat Genet*, 40(5), 616-22 (2008)
70. R. J. Hung, J. D. McKay, V. Gaboricau, P. Boffetta, M. Hashibe, D. Zaridze, A. Mukeria, N. Szeszenia-Dabrowska, J. Lissowska, P. Rudnai, E. Fabianova, D. Mates, V. Bencko, L. Foretova, V. Janout, C. Chen, G. Goodman, J. K. Field, T. Liloglou, G. Xinarianos, A. Cassidy, J. McLaughlin, G. Liu, S. Narod, H. E. Krokan, F. Skorpen, M. B. Elvestad, K. Hveem, L. Vatten, J. Linseisen, F. Clavel-Chapelon, P. Vineis, H. B. Bueno-de-Mesquita, E. Lund, C. Martinez, S. Bingham, T. Rasmuson, P. Hainaut, E. Riboli, W. Ahrens, S. Benhamou, P. Lagiou, D. Trichopoulos, I. Holcatova, F. Merletti, K. Kjaerheim, A. Agudo, G. Macfarlane, R. Talamini, L. Simonato, R. Lowry, D. I. Conway, A. Znaor, C. Healy, D. Zelenika, A. Boland, M. Delepine, M. Foglio, D. Lechner, F. Matsuda, H. Blanche, I. Gut, S. Heath, M. Lathrop and P. Brennan: A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. *Nature*, 452(7187), 633-7 (2008)
71. G. Lettre, A. U. Jackson, C. Gieger, F. R. Schumacher, S. I. Berndt, S. Sanna, S. Eyheramendy, B. F. Voight, J. L. Butler, C. Guiducci, T. Illig, R. Hackett, I. M. Heid, K. B. Jacobs, V. Lyssenko, M. Uda, M. Boehnke, S. J. Chanock, L. C. Groop, F. B. Hu, B. Isomaa, P. Kraft, L. Peltonen, V. Salomaa, D. Schlessinger, D. J. Hunter, R. B. Hayes, G. R. Abecasis, H. E. Wichmann, K. L. Mohlke and J. N. Hirschhorn: Identification of ten loci associated with height highlights new biological pathways in human growth. *Nat Genet*, 40(5), 584-91 (2008)
72. T. E. Thorgeirsson, F. Geller, P. Sulem, T. Rafnar, A. Wiste, K. P. Magnusson, A. Manolescu, G. Thorleifsson, H. Stefansson, A. Ingason, S. N. Stacey, J. T. Bergthorsson, S. Thorlacius, J. Gudmundsson, T. Jonsson, M. Jakobsdottir, J. Saemundsdottir, O. Olafsdottir, L. J. Gudmundsson, G. Bjornsdottir, K. Kristjansson, H. Skuladottir, H. J. Isaksson, T. Gudbjartsson, G. T. Jones, T. Mueller, A. Gottsater, A. Flex, K. K. Aben, F. de Vegt, P. F. Mulders, D. Isla, M. J. Vidal, L. Asin, B. Saez, L. Murillo, T. Blondal, H. Kolbeinnsson, J. G. Stefansson, I. Hansdottir, V. Runarsdottir, R. Pola, B. Lindblad, A. M. van Rij, B. Dieplinger, M. Haltmayer, J. I. Mayordomo, L. A. Kiemeny, S. E. Matthiasson, H. Oskarsson, T. Tyrfinngsson, D. F. Gudbjartsson, J. R. Gulcher, S. Jonsson, U. Thorsteinsdottir, A. Kong and K. Stefansson: A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. *Nature*, 452(7187), 638-42 (2008)

## Lung cancer susceptibility

73. J. D. McKay, R. J. Hung, V. Gaborieau, P. Boffetta, A. Chabrier, G. Byrnes, D. Zaridze, A. Mukeria, N. Szeszenia-Dabrowska, J. Lissowska, P. Rudnai, E. Fabianova, D. Mates, V. Bencko, L. Foretova, V. Janout, J. McLaughlin, F. Shepherd, A. Montpetit, S. Narod, H. E. Krokan, F. Skorpén, M. B. Elvestad, L. Vatten, I. Njolstad, T. Axelsson, C. Chen, G. Goodman, M. Barnett, M. M. Loomis, J. Lubinski, J. Matyjasik, M. Lener, D. Oszutowska, J. Field, T. Liloglou, G. Xinarianos, A. Cassidy, P. Vineis, F. Clavel-Chapelon, D. Palli, R. Tumino, V. Krogh, S. Panico, C. A. Gonzalez, J. Ramon Quiros, C. Martinez, C. Navarro, E. Ardanaz, N. Larranaga, K. T. Kham, T. Key, H. B. Bueno-de-Mesquita, P. H. Peeters, A. Trichopoulou, J. Linseisen, H. Boeing, G. Hallmans, K. Overvad, A. Tjonneland, M. Kumle, E. Riboli, D. Zelenika, A. Boland, M. Delepine, M. Foglio, D. Lechner, F. Matsuda, H. Blanche, I. Gut, S. Heath, M. Lathrop and P. Brennan: Lung cancer susceptibility locus at 5p15.33. *Nat Genet*, 40(12), 1404-6 (2008)
74. Y. Wang, P. Broderick, E. Webb, X. Wu, J. Vijayakrishnan, A. Matakidou, M. Qureshi, Q. Dong, X. Gu, W. V. Chen, M. R. Spitz, T. Eisen, C. I. Amos and R. S. Houlston: Common 5p15.33 and 6p21.33 variants influence lung cancer risk. *Nat Genet*, 40(12), 1407-9 (2008)
75. P. Liu, H. G. Vikis, D. Wang, Y. Lu, Y. Wang, A. G. Schwartz, S. M. Pinney, P. Yang, M. de Andrade, G. M. Petersen, J. S. Wiest, P. R. Fain, A. Gazdar, C. Gaba, H. Rothschild, D. Mandal, T. Coons, J. Lee, E. Kupert, D. Seminara, J. Minna, J. E. Bailey-Wilson, X. Wu, M. R. Spitz, T. Eisen, R. S. Houlston, C. I. Amos, M. W. Anderson and M. You: Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. *J Natl Cancer Inst*, 100(18), 1326-30 (2008)
76. M. R. Spitz, C. I. Amos, Q. Dong, J. Lin and X. Wu: The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. *J Natl Cancer Inst*, 100(21), 1552-6 (2008)
77. C. I. Amos, I. P. Gorlov, Q. Dong, X. Wu, H. Zhang, E. Y. Lu, P. Scheet, A. J. Greisinger, G. B. Mills and M. R. Spitz: Nicotinic acetylcholine receptor region on chromosome 15q25 and lung cancer risk among African Americans: a case-control study. *J Natl Cancer Inst*, 102(15), 1199-205 (2010)
78. C. Wu, Z. Hu, D. Yu, L. Huang, G. Jin, J. Liang, H. Guo, W. Tan, M. Zhang, J. Qian, D. Lu, T. Wu, D. Lin and H. Shen: Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese populations. *Cancer Res*, 69(12), 5065-72 (2009)
79. K. Shiraiishi, T. Kohno, H. Kunitoh, S. Watanabe, K. Goto, Y. Nishiwaki, Y. Shimada, H. Hirose, I. Saito, A. Kuchiba, S. Yamamoto and J. Yokota: Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese. *Carcinogenesis*, 30(1), 65-70 (2009)
80. P. Broderick, Y. Wang, J. Vijayakrishnan, A. Matakidou, M. R. Spitz, T. Eisen, C. I. Amos and R. S. Houlston: Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. *Cancer Res*, 69(16), 6633-41 (2009)
81. C. C. Chung, W. C. Magalhaes, J. Gonzalez-Bosquet and S. J. Chanock: Genome-wide association studies in cancer--current and future directions. *Carcinogenesis*, 31(1), 111-20 (2010)
82. J. Subramanian and R. Govindan: Lung cancer in never smokers: a review. *J Clin Oncol*, 25(5), 561-70 (2007)
83. S. Sun, J. H. Schiller and A. F. Gazdar: Lung cancer in never smokers--a different disease. *Nat Rev Cancer*, 7(10), 778-90 (2007)
84. G. K. Tokuhata and A. M. Lilienfeld: Familial aggregation of lung cancer in humans. *J Natl Cancer Inst*, 30, 289-312 (1963)
85. S. Avenevoli and K. R. Merikangas: Familial influences on adolescent smoking. *Addiction*, 98 Suppl 1, 1-20 (2003)
86. J. Lorenzo Bermejo and K. Hemminki: Familial lung cancer and aggregation of smoking habits: a simulation of the effect of shared environmental factors on the familial risk of cancer. *Cancer Epidemiol Biomarkers Prev*, 14(7), 1738-40 (2005)
87. K. C. Wilhelmssen and C. Ehlers: Heritability of substance dependence in a native American population. *Psychiatr Genet*, 15(2), 101-7 (2005)
88. M. A. Rossing: Genetic influences on smoking: candidate genes. *Environ Health Perspect*, 106(5), 231-8 (1998)
89. K. Blum, E. R. Braverman, J. M. Holder, J. F. Lubar, V. J. Monaster, D. Miller, J. O. Lubar, T. J. Chen and D. E. Comings: Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. *J Psychoactive Drugs*, 32 Suppl, i-iv, 1-112 (2000)
90. R. A. Schnoll, T. A. Johnson and C. Lerman: Genetics and smoking behavior. *Curr Psychiatry Rep*, 9(5), 349-57 (2007)
91. E. L. Goode, M. D. Badzioch, H. Kim, F. Gagnon, L. S. Rozek, K. L. Edwards and G. P. Jarvik: Multiple genome-wide analyses of smoking behavior in the Framingham Heart Study. *BMC Genet*, 4 Suppl 1, S102 (2003)
92. S. F. Saccone, M. L. Pergadia, A. Loukola, U. Broms, G. W. Montgomery, J. C. Wang, A. Agrawal, D. M. Dick, A. C. Heath, A. A. Todorov, H. Maunu, K. Heikkila, K. I. Morley, J. P. Rice, R. D. Todd, J. Kaprio, L. Peltonen, N. G. Martin, A. M. Goate and P. A. Madden: Genetic linkage to chromosome 22q12 for a heavy-smoking quantitative

## Lung cancer susceptibility

- trait in two independent samples. *Am J Hum Genet*, 80(5), 856-66 (2007)
93. L. J. Bierut, P. A. Madden, N. Breslau, E. O. Johnson, D. Hatsukami, O. F. Pomerleau, G. E. Swan, J. Rutter, S. Bertelsen, L. Fox, D. Fugman, A. M. Goate, A. L. Hinrichs, K. Konvicka, N. G. Martin, G. W. Montgomery, N. L. Saccone, S. F. Saccone, J. C. Wang, G. A. Chase, J. P. Rice and D. G. Ballinger: Novel genes identified in a high-density genome wide association study for nicotine dependence. *Hum Mol Genet*, 16(1), 24-35 (2007)
94. M. D. Li and M. Burmeister: New insights into the genetics of addiction. *Nat Rev Genet*, 10(4), 225-31 (2009)
95. K. O. Fagerstrom: Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. *Addict Behav*, 3(3-4), 235-41 (1978)
96. N. Kawakami, N. Takatsuka, S. Inaba and H. Shimizu: Development of a screening questionnaire for tobacco/nicotine dependence according to ICD-10, DSM-III-R, and DSM-IV. *Addict Behav*, 24(2), 155-66 (1999)
97. N. Sato, S. Kageyama, R. Chen, M. Suzuki, H. Mori, F. Tanioka, H. Yamada, T. Kamo, H. Tao, K. Shinmura, A. Nozawa and H. Sugimura: Association between neuropeptide Y receptor 2 polymorphism and the smoking behavior of elderly Japanese. *J Hum Genet* (2010)
98. N. Sato, S. Kageyama, R. Chen, M. Suzuki, F. Tanioka, T. Kamo, K. Shinmura, A. Nozawa and H. Sugimura: Association between neurexin 1 (NRXN1) polymorphisms and the smoking behavior of elderly Japanese. *Psychiatr Genet*, 20(3), 135-6 (2010)
99. Consortium, tobacco and genetics: Genome-wide meta-analyses identify multiple loci associated with smoking behavior. *Nat Genet*, 42(5), 441-7 (2010)
100. J. Z. Liu, F. Tozzi, D. M. Waterworth, S. G. Pillai, P. Muglia, L. Middleton, W. Berrettini, C. W. Knouff, X. Yuan, G. Waeber, P. Vollenweider, M. Preisig, N. J. Wareham, J. H. Zhao, R. J. Loos, I. Barroso, K. T. Khaw, S. Grundy, P. Barter, R. Mahley, A. Kesaniemi, R. McPherson, J. B. Vincent, J. Strauss, J. L. Kennedy, A. Farmer, P. McGuffin, R. Day, K. Matthews, P. Bakke, A. Gulsvik, S. Lucae, M. Ising, T. Brueckl, S. Horstmann, H. E. Wichmann, R. Rawal, N. Dahmen, C. Lamina, O. Polasek, L. Zgaga, J. Huffman, S. Campbell, J. Kooner, J. C. Chambers, M. S. Burnett, J. M. Devaney, A. D. Pichard, K. M. Kent, L. Satler, J. M. Lindsay, R. Waksman, S. Epstein, J. F. Wilson, S. H. Wild, H. Campbell, V. Vitart, M. P. Reilly, M. Li, L. Qu, R. Wilensky, W. Matthai, H. H. Hakonarson, D. J. Rader, A. Franke, M. Wittig, A. Schafer, M. Uda, A. Terracciano, X. Xiao, F. Busonero, P. Scheet, D. Schlessinger, D. St Clair, D. Rujescu, G. R. Abecasis, H. J. Grabe, A. Teumer, H. Volzke, A. Petersmann, U. John, I. Rudan, C. Hayward, A. F. Wright, I. Kolcic, B. J. Wright, J. R. Thompson, A. J. Balmforth, A. S. Hall, N. J. Samani, C. A. Anderson, T. Ahmad, C. G. Mathew, M. Parkes, J. Satsangi, M. Caulfield, P. B. Munroe, M. Farrall, A. Dominiczak, J. Worthington, W. Thomson, S. Eyre, A. Barton, V. Mooser, C. Francks and J. Marchini: Meta-analysis and imputation refines the association of 15q25 with smoking quantity. *Nat Genet*, 42(5), 436-40 (2010)
101. C. I. Amos, M. R. Spitz and P. Cinciripini: Chipping away at the genetics of smoking behavior. *Nat Genet*, 42(5), 366-8 (2010)
102. Yamagiwa Memorial Foundation: Collected papers on artificial production of cancer. Maruzen, Tokyo (1965)
103. E. C. Miller: Some current perspectives on chemical carcinogenesis in humans and experimental animals: Presidential Address. *Cancer Res*, 38(6), 1479-96 (1978)
104. T. Sugimura: Studies on environmental chemical carcinogenesis in Japan. *Science*, 233(4761), 312-8 (1986)
105. S. Yoshii, M. Tanaka, Y. Otsuki, T. Fujiyama, H. Kataoka, H. Arai, H. Hanai and H. Sugimura: Involvement of alpha-PAK-interacting exchange factor in the PAK1-c-Jun NH(2)-terminal kinase 1 activation and apoptosis induced by benzo[a]pyrene. *Mol Cell Biol*, 21(20), 6796-807 (2001)
106. K. Shinmura, M. Iwaizumi, H. Igarashi, K. Nagura, H. Yamada, M. Suzuki, K. Fukasawa and H. Sugimura: Induction of centrosome amplification and chromosome instability in p53-deficient lung cancer cells exposed to benzo[a]pyrene diol epoxide (B[a]PDE). *J Pathol*, 216(3), 365-74 (2008)
107. B. J. Song, H. V. Gelboin, S. S. Park, G. C. Tsokos and F. K. Friedman: Monoclonal antibody-directed radioimmunoassay detects cytochrome P-450 in human placenta and lymphocytes. *Science*, 228(4698), 490-2 (1985)
108. R. B. Everson, E. Randerath, R. M. Santella, R. C. Cefalo, T. A. Avitts and K. Randerath: Detection of smoking-related covalent DNA adducts in human placenta. *Science*, 231(4733), 54-7 (1986)
109. R. A. Kanaly, T. Hanaoka, H. Sugimura, H. Toda, S. Matsui and T. Matsuda: Development of the adductome approach to detect DNA damage in humans. *Antioxid Redox Signal*, 8(5-6), 993-1001 (2006)
110. P. H. Chou, S. Kageyama, S. Matsuda, K. Kanemoto, Y. Sasada, M. Oka, K. Shinmura, H. Mori, K. Kawai, H. Kasai, H. Sugimura and T. Matsuda: Detection of lipid peroxidation-induced DNA adducts caused by 4-oxo-2(E)-nonenal and 4-oxo-2(E)-hexenal in human autopsy tissues. *Chem Res Toxicol*, 23(9), 1442-8 (2010)
111. A. F. Gazdar and P. Boffetta: A risky business--identifying susceptibility loci for lung cancer. *J Natl Cancer Inst*, 102(13), 920-3 (2010)

## Lung cancer susceptibility

112. T. Truong, R. J. Hung, C. I. Amos, X. Wu, H. Bickeboller, A. Rosenberger, W. Sauter, T. Illig, H. E. Wichmann, A. Risch, H. Dienemann, R. Kaaks, P. Yang, R. Jiang, J. K. Wiencke, M. Wrensch, H. Hansen, K. T. Kelsey, K. Matsuo, K. Tajima, A. G. Schwartz, A. Wenzlaff, A. Seow, C. Ying, A. Staratschek-Jox, P. Nurnberg, E. Stoelben, J. Wolf, P. Lazarus, J. E. Muscat, C. J. Gallagher, S. Zienolddiny, A. Haugen, H. F. van der Heijden, L. A. Kiemeny, D. Isla, J. I. Mayordomo, T. Rafnar, K. Stefansson, Z. F. Zhang, S. C. Chang, J. H. Kim, Y. C. Hong, E. J. Duell, A. S. Andrew, F. Lejbkiewicz, G. Rennert, H. Muller, H. Brenner, L. Le Marchand, S. Benhamou, C. Bouchardy, M. D. Teare, X. Xue, J. McLaughlin, G. Liu, J. D. McKay, P. Brennan and M. R. Spitz: Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. *J Natl Cancer Inst*, 102(13), 959-71 (2010)

113. R. D. Dowell, O. Ryan, A. Jansen, D. Cheung, S. Agarwala, T. Danford, D. A. Bernstein, P. A. Rolfé, L. E. Heisler, B. Chin, C. Nislow, G. Giaever, P. C. Phillips, G. R. Fink, D. K. Gifford and C. Boone: Genotype to phenotype: a complex problem. *Science*, 328(5977), 469 (2010)

**Key Words:** Review, Lung cancer susceptibility, Genome-wide association study (GWAS), Single nucleotide polymorphism (SNP), Adductome, DNA adducts, DNA repair, CYP, Smoking behavior, Review

**Send correspondence to:** Haruhiko Sugimura, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, Japan 431-3192, Tel: 81-53-435-2220, Fax: 81-53-435-2225, E-mail: hsugimur@hama-med.ac.jp

## Lung cancer susceptibility

### List of required items

Note: This galley is provided to you for text correction. Please read this galley with great care and make all necessary text changes. Following submission of the first galley, text changes will not be possible without ordering an entire reprocessing step. If required, the form can be obtained at (<http://www.bioscience.org/submit.doc>).

The following marked items are not provided or formatted according to per FBS style. Please format or provide the item(s) indicated below. Details on proper formatting of the document and instruction for obtaining doi linked references is available at the end of the publication forms.

Table 1 is not cited in text. Highlight citation in first galley in red font and return the galley

Please submit all the following together in a single Email to [fbs@bioscience.org](mailto:fbs@bioscience.org). Do not send on different dates

Revised first galley

Note: The return of this galley requires your approval

I am the corresponding author

1. I have read this galley and have made all necessary text changes
2. I approve the publication of this galley without any further text changes.
3. If I wish to request any further changes not included in this galley, I will submit the reprocessing form (<http://www.bioscience.org/submit.doc>).

I provide my approval

Approved

(click this box and then select "Checked". The box will change to )

Place your name here:

Haruhiko Sugimura

Place your E-mail here: [hsugimur@hama-med.ac.jp](mailto:hsugimur@hama-med.ac.jp)

Place date here: Jan 26, 2011

## KIF5B-RET fusions in lung adenocarcinoma

Takashi Kohno<sup>1,15</sup>, Hitoshi Ichikawa<sup>2,15</sup>, Yasushi Totoki<sup>3</sup>, Kazuki Yasuda<sup>4</sup>, Masaki Hiramoto<sup>4</sup>, Takao Nammo<sup>4</sup>, Hiromi Sakamoto<sup>2</sup>, Koji Tsuta<sup>5</sup>, Koh Furuta<sup>5</sup>, Yoko Shimada<sup>1</sup>, Reika Iwakawa<sup>6</sup>, Hideaki Ogiwara<sup>1</sup>, Takahiro Oike<sup>6</sup>, Masato Enari<sup>7</sup>, Aaron J Schetter<sup>8</sup>, Hirokazu Okayama<sup>6,8</sup>, Aage Haugen<sup>9</sup>, Vidar Skaug<sup>9</sup>, Suenori Chiku<sup>10</sup>, Itaru Yamanaka<sup>11</sup>, Yasuhito Arai<sup>3</sup>, Shun-ichi Watanabe<sup>12</sup>, Ikuo Sekine<sup>13</sup>, Seishi Ogawa<sup>14</sup>, Curtis C Harris<sup>8</sup>, Hitoshi Tsuda<sup>5</sup>, Teruhiko Yoshida<sup>2</sup>, Jun Yokota<sup>6</sup> & Tatsuhiko Shibata<sup>3</sup>

We identified in-frame fusion transcripts of *KIF5B* (the kinesin family 5B gene) and the *RET* oncogene, which are present in 1–2% of lung adenocarcinomas (LADCs) from people from Japan and the United States, using whole-transcriptome sequencing. The *KIF5B-RET* fusion leads to aberrant activation of RET kinase and is considered to be a new driver mutation of LADC because it segregates from mutations or fusions in *EGFR*, *KRAS*, *HER2* and *ALK*, and a RET tyrosine kinase inhibitor, vandetanib, suppresses the fusion-induced anchorage-independent growth activity of NIH3T3 cells.

A considerable proportion of LADCs, the most common histological type of lung cancer that comprises ~40% of the total cases, develops through activation of oncogenes, for example, somatic mutations in *EGFR* (10–50% of cases) or *KRAS* (10–30% of cases) or fusion of *ALK* (5% of cases), in a mutually exclusive manner<sup>1–4</sup>. Tyrosine kinase inhibitors (TKIs) targeting the EGFR and ALK proteins are effective in the treatment of LADCs that carry *EGFR* mutations and *ALK* fusions<sup>1–3</sup>, respectively.

We performed whole-transcriptome sequencing (RNA sequencing)<sup>5</sup> of 30 LADC specimens from Japanese individuals to identify new chimeric fusion transcripts that could be targets for therapy<sup>3,5,6</sup>. These LADCs were 2 carcinomas with *EML4-ALK* fusions, 4 with *EGFR* or *KRAS* mutations and 24 without these fusions or mutations (Supplementary Table 1). Identifying candidate fusions represented by >20 paired-end reads and validation by Sanger sequencing of the RT-PCR products (Supplementary Methods) led to the identification of seven fusion transcripts, including *EML4-ALK* (Supplementary Table 1). We detected one of these fusions between *KIF5B* on chromosome

10p11.2 and *RET* on chromosome 10q11.2 in subject BR0020 (Fig. 1 and Supplementary Fig. 1a). We then further investigated this fusion, as fusions between *RET* and genes other than *KIF5B* have previously been shown to drive papillary thyroid tumor formation<sup>6,7</sup>.

RT-PCR and a Sanger sequencing analysis of 319 LADC specimens from Japanese individuals (Supplementary Table 2), including 30 that had been subjected to whole-transcriptome sequencing, revealed that 1.9% (6 out of 319) expressed *KIF5B-RET* fusion transcripts (Fig. 1b and Supplementary Fig. 1b). We identified four variants in these six tumors, and all of these variants were in frame (Fig. 1a).

A genomic PCR analysis of the six tumors that were positive for RET fusions revealed somatic fusions of the *KIF5B* introns 15, 16, 23 or 24 at chromosome 10p11.2 with the *RET* introns 7 or 11 at 10q11.2 (Supplementary Fig. 1c,d), indicating that a chromosomal inversion had occurred between the long and short arms in the centromeric region of chromosome 10 (Supplementary Figs. 1e and 2). We verified this chromosomal inversion using fluorescence *in situ* hybridization, which revealed a split in the signals for the probes that flank the *RET* translocation sites in tumors positive for the *KIF5B-RET* fusion (Supplementary Fig. 2).

The tumors positive for the *KIF5B-RET* fusion were all well or moderately differentiated (Table 1 and Supplementary Fig. 3). None of the subjects with these tumors had a history of thyroid cancer, and none showed abnormal findings in their thyroid tissues as determined by computed tomography or positron emission tomography before surgery for LADC. All five examined tumors with the *KIF5B-RET* fusion were positive for thyroid transcription factor 1 (TTF-1) and napsin A aspartic proteinase (Napsin A)<sup>8</sup> but were negative for thyroglobulin<sup>9</sup>, indicating that they were of pulmonary origin (Table 1 and Supplementary Fig. 3). The LADCs that were positive for the *KIF5B-RET* fusion showed twofold to 30-fold higher *RET* expression than non-cancerous lung tissues (Fig. 1b and Supplementary Figs. 4 and 5). An immunohistochemical analysis using an antibody against the C-terminal region of the RET protein detected positive cytoplasmic staining in the tumor cells of the fusion-positive LADCs (Table 1 and Supplementary Fig. 3b) but did not detect this staining in any of the non-cancerous lung cells. A western blot analysis confirmed the expression of the fusion proteins in the LADCs (Supplementary Fig. 6).

To address the prevalence of *KIF5B-RET* fusions in LADCs from individuals of non-Asian ancestry, we examined LADCs in cohorts from the United States and Norway (Supplementary Table 2). We detected a fusion transcript in 1 of the 80 (1.3%) subjects from the

<sup>1</sup>Division of Genome Biology, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan. <sup>2</sup>Division of Genetics, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan. <sup>3</sup>Division of Cancer Genomics, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan. <sup>4</sup>Department of Metabolic Disorder, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan. <sup>5</sup>Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan. <sup>6</sup>Division of Multistep Carcinogenesis, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan. <sup>7</sup>Division of Refractory Cancer Research, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan. <sup>8</sup>Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, US National Institutes of Health, Bethesda, Maryland, USA. <sup>9</sup>Section of Toxicology, Department of Chemical and Biological Working Environment, National Institute of Occupational Health, Oslo, Norway. <sup>10</sup>Science Solutions Division, Mizuho Information and Research Institute, Chiyoda-ku, Tokyo, Japan. <sup>11</sup>Statistical Genetics Analysis Division, StaGen, Taito-ku, Tokyo, Japan. <sup>12</sup>Division of Thoracic Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan. <sup>13</sup>Division of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan. <sup>14</sup>Cancer Genomics Project, University of Tokyo, Bunkyo-ku, Tokyo, Japan. <sup>15</sup>These authors equally contributed to this work. Correspondence should be addressed to T.K. (tkkohno@ncc.go.jp).


Received 23 August 2011; accepted 16 December 2011; published online 12 February 2012; doi:10.1038/nm.2644



## BRIEF COMMUNICATIONS

**Figure 1** *KIF5B-RET* fusions in LADC.

(a) Schematic representations of the wild-type *KIF5B* and *RET* proteins as well as the four fusion variants identified in this study. The breakpoints for each variant are indicated with red lines. CC, coiled coil; TM, transmembrane. (b) Detection of *KIF5B-RET* fusions by RT-PCR. RT-PCR products for the *RET* kinase domain (exons 12 and 13) and *GAPDH* are shown below. Six LADCs positive for *KIF5B-RET* fusions (T) are shown, with four corresponding non-cancerous lung tissues (N), a no-template control (NTC) and one LADC that was negative for the fusion (BR0019). (c) Activation of *RET* kinase activity in the *KIF5B-RET* protein and the suppression of this activity by vandetanib. H1299 lung cancer cells were transfected with an empty vector, wild-type *RET* (*RET*) or *KIF5B-RET* expression plasmids and treated either with DMSO (serum) or vandetanib, as indicated. The ratios of phosphorylated Tyr905 (pTyr905) *RET* to total *RET* signals with respect to wild-type *RET* after the serum treatment are listed below the gels. (d) Anchorage-independent growth of NIH3T3 cells expressing *KIF5B-RET* protein and the suppression of this growth by vandetanib. Representative pictures of colonies without vandetanib treatment (top). Scale bars, 50  $\mu$ m. Bar graph showing the percentage ( $\pm$  s.d.) of colonies formed after treatment with the indicated amounts of vandetanib (average results of three independent experiments) with respect to those formed by DMSO-treated cells. The study was approved by the institutional review boards of institutions participating in this study.



United States (an individual of European ancestry) (Supplementary Fig. 7), but we detected no fusion transcripts in the 34 subjects from Norway (Supplementary Table 3); *KIF5B-RET* fusions occurred in 1–2% of LADCs in both Asians and non-Asians. The individual from the United States with the *RET* fusion was classified as an ‘ever smoker’, whereas the six individuals from Japan with the *RET* fusion were ‘never smokers’ (Table 1). Therefore, prevalence of LADC with regard to smoking status is unclear. We did not detect the *KIF5B-RET* fusion in other major subtypes of lung cancer, including 234 squamous-cell, 17 large-cell and 20 small-cell lung carcinomas (Supplementary Table 3). The fusion was also not present in other types of adenocarcinomas, including those of the ovary ( $n = 100$ ) and colon ( $n = 200$ ) (data not shown), suggesting that it is specific to LADC.

All seven subjects with LADC harboring the *KIF5B-RET* fusion were negative for *EGFR*, *KRAS* and *ALK* mutations or fusions and were negative for mutations in *HER2*, which is an additional driver mutation in LADC<sup>10</sup> (Table 1 and Supplementary Table 4). The mutually exclusive nature of the *RET* fusions and other oncogenic alterations<sup>1,2,11</sup> suggests that the *KIF5B-RET* fusion is a driver mutation. All proteins encoded by the four *KIF5B-RET* fusion variants contained the *KIF5B* coiled-coil domain, which functions in protein dimerization<sup>12</sup>, and retained the

full *RET* kinase domain, similar to other types of oncogenic *RET* fusions observed in thyroid tumors (Fig. 1a)<sup>13</sup>. The *KIF5B-RET* proteins are likely to form a homodimer through the coiled-coil domain of *KIF5B*, causing an aberrant activation of the kinase function of *RET* in a manner similar to the *PTC-RET* and *KIF5B-ALK* fusions<sup>7,14</sup>. In fact, the N-terminal portion of the *KIF5B* coiled-coil region, which is retained in all variants, has been predicted to have the ability to dimerize through two coiled-coil structures<sup>15</sup>. Consistently, when the *KIF5B-RET* variant 1 was exogenously expressed in H1299 human lung cancer cells without wild-type or fusion *RET* expression, Tyr905, which is located in the activation loop of the *RET* kinase site<sup>15,16</sup>, was phosphorylated in the absence of serum stimulation, indicating an aberrant activation of *RET* kinase<sup>16,17</sup> by fusion with *KIF5B* (Fig. 1c). This phosphorylation was suppressed by vandetanib, a TKI against *RET* (as well as other tyrosine kinases, including *EGFR* and *VEGFR*)<sup>18</sup> (Fig. 1c and Supplementary Fig. 8).

Expression of exogenous *KIF5B-RET*, but not *KIF5B-RET-KD* (a kinase-dead mutant corresponding to S765P in wild-type *RET*<sup>17</sup>), induced morphological transformation (Supplementary Fig. 9) and anchorage-independent growth of NIH3T3 fibroblasts in a way that was analogous to the induction caused by mutant *KRAS* (*KRASV12*) (Fig. 1d). Consistently, phosphorylation of Tyr905 was higher in the *KIF5B-RET*

**Table 1** Characteristics of lung adenocarcinomas with the *KIF5B-RET* fusion

Sample	Country	Sex	Age <sup>a</sup>	Smoking	<i>KIF5B-RET</i> fusion <sup>b</sup>	Pathological stage	Pathological findings	<i>RET</i> staining	TTF-1 staining	Napsin A staining	Thyroglobulin staining
BR0020	Japan	Male	57	Never	K15; R12 (variant 1)	IIb	Moderately differentiated ADC	+	+	+	–
BR1001	Japan	Female	65	Never	K15; R12 (variant 1)	IB	Well differentiated ADC	+	+	+	–
BR1002	Japan	Female	64	Never	K15; R12 (variant 1)	IB	Well differentiated ADC	+	+	+	–
BR0030	Japan	Male	57	Never	K16; R12 (variant 2)	IA	Well differentiated ADC	+	+	+	–
BR1003	Japan	Male	28	Never	K23; R12 (variant 3)	IA	Well differentiated ADC	+	+	+	–
BR1004	Japan	Female	71	Never	K24; R8 (variant 4)	IA	Moderately differentiated ADC	NT	NT	NT	NT
NCI1580	USA	Male	63	Ever <sup>c</sup>	K15; R12 (variant 1)	II	Moderately differentiated ADC	NT	NT	NT	NT

<sup>a</sup>Age in years. <sup>b</sup>Fused exon numbers of *KIF5B* (K) and *RET* (R); and variant types (in parentheses) are shown. None of the subjects had oncogenic *EGFR*, *KRAS*, *HER2* or *ALK* mutations or fusions. <sup>c</sup>The number of pack years smoked for this subject is not known. NT, not tested.

protein than in the KIF5B-RET-KD protein. The anchorage-independent growth induced by *KIF5B-RET* was suppressed by treatment with vandetanib (<1  $\mu\text{M}$ ), whereas the growth induced by mutant *KRAS* was not (Fig. 1d). These results are similar to those observed for *RET* fusions in thyroid cancer<sup>19</sup>. We also detected phosphorylation of the KIF5B-RET protein at Tyr905 in fusion-positive LADC specimens (Supplementary Fig. 6). These results suggest that the *RET* fusions are a previously unidentified LADC driver mutation and a potential target for existing TKIs, including vandetanib, which has been recently approved by the US Food and Drug Administration for the treatment of thyroid cancer<sup>18</sup>. Further studies are warranted to promote molecular subtype diagnoses and personalized therapy options for LADC. For this purpose, both the clinical and biological features of this fusion are being investigated. For further information, please see the **Supplementary Note and Supplementary Tables 5 and 6**.

Note: Supplementary information is available on the Nature Medicine website.

#### ACKNOWLEDGMENTS

This work was supported in part by the program for promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio), Grants-in-Aid from the Ministry of Health, Labour and Welfare for the 3rd-term Comprehensive 10-year Strategy for Cancer Control, the National Cancer Center Research and Development Fund and the Norwegian Cancer Society. National Cancer Center Biobank is supported by the National Cancer Center Research and Development Fund, Japan. We thank T. Urushidate, S. Ohashi, S. Mitani, K. Yokozawa, S. Wakai, C. Otsubo and H. Isomura of the National Cancer Center and D. Suzuki and K. Nagase of the National Center for Global Health and Medicine for technical assistance. We also thank J.D. Minna and L. Girard of the University of Texas Southwestern Medical Center, K. Kumamoto of Saitama Medical University and A. Okamoto of Jikei University for *RET* fusion screening, N. Morii of the National Institute of Advanced Industrial Science and Technology (AIST) for thermodynamic characterization of the KIF5B protein and M. Maekawa of the GSP laboratory for rapid preparation of the FISH probes.

#### AUTHOR CONTRIBUTIONS

RNA sequencing: H.L., K.Y., M.H., T.N. and H.S. Sequence data processing: Y.T., S.C. and I.Y. Molecular biological analyses: T.K., Y.S., R.J., H. Ogiwara, T.O., M.E., A.J.S., H. Okayama, A.H., Y.A. and S.O. Clinical and pathological analyses: K.T., K.F., V.S., S.W., I.S. and H.T. Manuscript writing: T.K., H.L. and T.S. Study design: T.K., H.L., C.C.H., T.Y., J.Y. and T.S.

#### COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Published online at <http://www.nature.com/naturemedicine/>.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

- Janku, F., Stewart, D.J. & Kurzrock, R. *Nat. Rev. Clin. Oncol.* **7**, 401–414 (2010).
- Gerber, D.E. & Minna, J.D. *Cancer Cell* **18**, 548–551 (2010).
- Lovly, C.M. & Carbone, D.P. *Nat. Rev. Clin. Oncol.* **8**, 68–70 (2011).
- Soda, M. *et al. Nature* **448**, 561–566 (2007).
- Meyerson, M., Gabriel, S. & Getz, G. *Nat. Rev. Genet.* **11**, 685–696 (2010).
- Mani, R.S. & Chinnaiyan, A.M. *Nat. Rev. Genet.* **11**, 819–829 (2010).
- Wells, S.A. Jr. & Santoro, M. *Clin. Cancer Res.* **15**, 7119–7123 (2009).
- Bishop, J.A., Sharma, R. & Illei, P.B. *Hum. Pathol.* **41**, 20–25 (2010).
- DeLellis, R.A., Shin, S.J. & Treaba, D.O. *Immunohistology of Endocrine Tumors* (Saunders, Philadelphia, Pennsylvania, USA, 2010).
- Shigematsu, H. *et al. Cancer Res.* **65**, 1642–1646 (2005).
- Herbst, R.S., Heymach, J.V. & Lippman, S.M. *N. Engl. J. Med.* **359**, 1367–1380 (2008).
- Hirokawa, N., Noda, Y., Tanaka, Y. & Niwa, S. *Nat. Rev. Mol. Cell Biol.* **10**, 682–696 (2009).
- Jhiani, S.M. *Oncogene* **19**, 5590–5597 (2000).
- Takeuchi, K. *et al. Clin. Cancer Res.* **15**, 3143–3149 (2009).
- Morii, H., Takenawa, T., Arisaka, F. & Shimizu, T. *Biochemistry* **36**, 1933–1942 (1997).
- Vitagliano, D. *et al. Endocr. Relat. Cancer* **18**, 1–11 (2011).
- Croyle, M. *et al. Cancer Res.* **68**, 4183–4191 (2008).
- Commander, H., Whiteside, G. & Perry, C. *Drugs* **71**, 1355–1365 (2011).
- Carlomagno, F. *et al. Cancer Res.* **62**, 7284–7290 (2002).





## Identification of Genes Upregulated in *ALK*-Positive and *EGFR/KRAS/ALK*-Negative Lung Adenocarcinomas

Hirokazu Okayama<sup>1,2,10</sup>, Takashi Kohno<sup>2</sup>, Yuko Ishii<sup>1,2</sup>, Yoko Shimada<sup>2</sup>, Kouya Shiraishi<sup>2</sup>, Reika Iwakawa<sup>1</sup>, Koh Furuta<sup>5</sup>, Koji Tsuta<sup>5</sup>, Tatsuhiro Shibata<sup>3</sup>, Seiichiro Yamamoto<sup>7</sup>, Shun-ichi Watanabe<sup>6</sup>, Hiromi Sakamoto<sup>4</sup>, Kensuke Kumamoto<sup>10</sup>, Seiichi Takenoshita<sup>10</sup>, Noriko Gotoh<sup>8</sup>, Hideaki Mizuno<sup>11,12</sup>, Akinori Sarai<sup>11</sup>, Shuichi Kawano<sup>9</sup>, Rui Yamaguchi<sup>9</sup>, Satoru Miyano<sup>9</sup>, and Jun Yokota<sup>1</sup>

### Abstract

Activation of the *EGFR*, *KRAS*, and *ALK* oncogenes defines 3 different pathways of molecular pathogenesis in lung adenocarcinoma. However, many tumors lack activation of any pathway (triple-negative lung adenocarcinomas) posing a challenge for prognosis and treatment. Here, we report an extensive genome-wide expression profiling of 226 primary human stage I–II lung adenocarcinomas that elucidates molecular characteristics of tumors that harbor *ALK* mutations or that lack *EGFR*, *KRAS*, and *ALK* mutations, that is, triple-negative adenocarcinomas. One hundred and seventy-four genes were selected as being upregulated specifically in 79 lung adenocarcinomas without *EGFR* and *KRAS* mutations. Unsupervised clustering using a 174-gene signature, including *ALK* itself, classified these 2 groups of tumors into *ALK*-positive cases and 2 distinct groups of triple-negative cases (groups A and B). Notably, group A triple-negative cases had a worse prognosis for relapse and death, compared with cases with *EGFR*, *KRAS*, or *ALK* mutations or group B triple-negative cases. In *ALK*-positive tumors, 30 genes, including *ALK* and *GRIN2A*, were commonly overexpressed, whereas in group A triple-negative cases, 9 genes were commonly overexpressed, including a candidate diagnostic/therapeutic target *DEPDC1*, that were determined to be critical for predicting a worse prognosis. Our findings are important because they provide a molecular basis of *ALK*-positive lung adenocarcinomas and triple-negative lung adenocarcinomas and further stratify more or less aggressive subgroups of triple-negative lung ADC, possibly helping identify patients who may gain the most benefit from adjuvant chemotherapy after surgical resection. *Cancer Res*; 72(1); 100–111. ©2011 AACR.

### Introduction

Lung cancer is the leading cause of cancer death worldwide (1, 2). Adenocarcinoma, which accounts for more than 50% of non-small-cell lung cancers (NSCLC), is the most frequent type and is increasing. Lung adenocarcinoma has a heterogeneous nature in various aspects, including clinicopathologic features

(3). Recent molecular studies have revealed at least 3 major molecular pathways for the development of lung adenocarcinoma (4–8). A considerable fraction (30%–60%) of lung adenocarcinomas develops through acquisition of mutations either in the *EGFR*, *KRAS*, or *ALK* genes in a mutually exclusive manner, and the remaining lung adenocarcinomas, that is, those without *EGFR*, *KRAS*, and *ALK* mutations (herein designated "triple-negative adenocarcinomas"), develop with mutations of several other genes. *HER2*, *BRAF*, etc. are known to be mutated also mutually exclusively with the *EGFR*, *KRAS*, and *ALK* genes; however, frequencies of their mutations are very low (<5%; refs. 4–7). Therefore, genes responsible for the development of triple-negative adenocarcinomas are largely unknown.

Mutations in the *EGFR* gene are prevalent in females and never-smokers, and the frequencies are considerably higher in Asians (40%–60%) than in Europeans/Americans (~10%; refs. 5–7, 9). *EGFR* mutations make tumor cells dependent on epidermal growth factor receptor (EGFR) signaling and define patients who respond to EGFR tyrosine kinase inhibitors (TKI), such as gefitinib (10, 11). On the other hand, mutations in the *KRAS* gene occur predominantly in males and ever-smokers, and their frequencies are higher in Europeans/Americans (>15%) than in Asians (10%; ref. 9). Specific inhibitors against *KRAS* activity are being developed (12). Therefore, clinicopathologic features of lung adenocarcinomas with *EGFR* mutations (herein designated "*EGFR*-positive adenocarcinomas") and

**Authors' Affiliations:** Divisions of <sup>1</sup>Multistep Carcinogenesis, <sup>2</sup>Genome Biology, <sup>3</sup>Cancer Genomics and <sup>4</sup>Genetics, National Cancer Center Research Institute; <sup>5</sup>Division of Pathology and Clinical Laboratories and <sup>6</sup>Thoracic Surgery Division, National Cancer Center Hospital; <sup>7</sup>Cancer Information Services and Surveillance Division, Center for Cancer Control and Information Services, National Cancer Center; <sup>8</sup>Division of Systems Biomedical Technology and <sup>9</sup>Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo; <sup>10</sup>Department of Organ Regulatory Surgery, Fukushima Medical University School of Medicine, Fukushima; <sup>11</sup>Department of Biosciences and Bioinformatics, Kyushu Institute of Technology, Fukuoka; and <sup>12</sup>Discovery Science & Technology Department, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan

**Note:** Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

**Corresponding Author:** Jun Yokota, Division of Multistep Carcinogenesis, National Cancer Center Research Institute, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan. Phone: 81-3-3547-5272; Fax: 81-3-3542-0807; E-mail: jyokota@ncc.go.jp

doi: 10.1158/0008-5472.CAN-11-1403

©2011 American Association for Cancer Research.

those with *KRAS* mutations (herein designated "*KRAS*-positive adenocarcinomas") are considerably different from each other. Recently, a small subset of *EGFR*- and *KRAS*-negative lung adenocarcinomas (~5%) was shown to have rearrangements of the *ALK* gene generating gene fusion transcripts (13), and patients with *ALK* rearrangements tend to be younger and have little or no smoking histories (4, 6–8). Because lung adenocarcinoma cells with *ALK* rearrangements (herein designated "*ALK*-positive adenocarcinomas") are specifically sensitive to ALK TKIs, *ALK*-positive adenocarcinomas have been recently considered to be another subset of adenocarcinomas by considering the differences in therapeutic targets (4, 6–8). In contrast, clinicopathologic features of triple-negative lung adenocarcinomas have not been precisely characterized because of the lack of sufficient genetic information in these adenocarcinomas.

There have been several studies which attempted to characterize gene expression profiles in particular types of lung adenocarcinoma, including *EGFR*-positive and *KRAS*-positive adenocarcinomas (14–17). However, such information is limited for *ALK*-positive adenocarcinomas and triple-negative adenocarcinomas. Therefore, in this study, we aimed to elucidate clinicopathologic features and gene expression profiles of *ALK*-positive adenocarcinomas and triple-negative adenocarcinomas in comparison with those of *EGFR*-positive adenocarcinomas and *KRAS*-positive adenocarcinomas. We conducted a genome-wide gene expression profiling of 226 lung adenocarcinomas, consisting of 127 *EGFR*-positive adenocarcinomas, 20 *KRAS*-positive adenocarcinomas, 11 *ALK*-positive adenocarcinomas, and 68 triple-negative adenocarcinomas. To identify genes useful for molecular diagnosis and applicable to targeted therapy of *ALK*-positive adenocarcinomas and triple-negative adenocarcinomas, we focused on genes that were upregulated in these adenocarcinomas by selecting genes with low expression in *EGFR*-positive and *KRAS*-positive adenocarcinomas. Several genes were identified as being specifically and significantly upregulated in *ALK*-positive adenocarcinomas. In particular, the *ALK* gene itself was highly expressed exclusively in *ALK*-positive adenocarcinomas. More importantly, a distinct group of triple-negative adenocarcinomas with unfavorable outcome was identified. This group of triple-negative adenocarcinomas showed much worse prognosis than the other group of triple-negative adenocarcinomas, *EGFR*-positive adenocarcinomas, *KRAS*-positive adenocarcinomas, and *ALK*-positive adenocarcinomas. Several genes were identified as being upregulated and critical for predicting prognosis of patients in this group of adenocarcinomas.

## Materials and Methods

### Patients

The tumors were pathologically classified according to the TNM classification of malignant tumors (18). A total of 226 lung adenocarcinoma cases subjected to expression profiling were selected from 393 stage I–II cases who underwent potential curative resection between 1998 and 2008 at the National Cancer Center Hospital as follows (ref. 19; Supplementary Fig. S1). Among the 393 cases, 363 cases, consisting of 305 stage I

and 58 stage II cases, were eligible by the criteria of cases who did not receive any neoadjuvant therapies before surgery and had not been diagnosed with cancer in the 5 years before lung adenocarcinoma diagnosis. All 58 stage II cases were subjected to expression profiling. The 305 stage I cases included 37 cases with relapse and 268 cases without relapse. To improve statistical efficiency, all the 37 relapsed cases and 131 matched unreleased cases selected by the incidence density sampling method (20, 21) were subjected to expression profiling. In total, 226 cases, consisting of 168 stage I and 58 stage II cases, were subjected to the expression profiling. Among the 226 cases, 204 who received complete resection (i.e., free resection margins and no involvement of mediastinal lymph nodes examined by mediastinal dissection) and did not receive postoperative chemotherapy and/or radiotherapy, unless relapsed, were subjected to survival analyses. This study was approved by the Institutional Review Boards of the National Cancer Center.

### Microarray experiments and data processing

Total RNA was extracted using TRIzol reagent (Invitrogen), purified by an RNeasy kit (Qiagen), and qualified with a model 2100 Bioanalyzer (Agilent). All samples showed RNA Integrity Numbers more than 6.0 and were subjected to microarray experiments. Two micrograms of total RNA were labeled using a 5X MEGAscript T7 Kit (Ambion) and analyzed by Affymetrix U133Plus2.0 arrays. The data were processed by the MAS5 algorithm, and the mean expression level of a total of 54,675 probes was adjusted to 1,000 for each sample. Microarray data are available at National Center for Biotechnology Information Gene Expression Omnibus (GSE31210).

### Probe selection for unsupervised clustering

One hundred and seventy-four genes (190 probes), preferentially expressed in *ALK*-positive and triple-negative adenocarcinomas, were selected by the following criteria; probes whose expression levels were less than 1,000 in any adenocarcinomas with *EGFR* or *KRAS* mutations, and probes whose averaged expression levels in *ALK*-positive and triple-negative adenocarcinomas were more than 1.5-fold higher than those in *EGFR*-positive and *KRAS*-positive adenocarcinomas with *P* values less than 0.05 by *t* test. Expression levels for these 190 probes were log-transformed and median-centered, both for probes and samples, and were subjected to an unsupervised hierarchical clustering. The clustering was done by the centroid linkage method using the Cluster 3.0 program, and the results were visualized using the Java Treeview program (22).

### Mutation analyses

Genomic DNAs from all 226 lung adenocarcinomas were analyzed for *EGFR* and *KRAS* mutations by the high-resolution melting method as described (23, 24). Total RNAs from the 226 adenocarcinomas were examined for expression of fusion transcripts between *ALK* and *EML4* or *KIF5* using a multiplex reverse transcription PCR (RT-PCR) method (25).

### Statistics

Cumulative survival was estimated by the Kaplan–Meier method, and differences in the survivals between 2 groups were

analyzed by log-rank test. Influences of variables on relapse-free survival (RFS) and overall survival (OS) were evaluated by uni- and multivariate analyses of the Cox proportional hazard model. For all analyses, smoking status was polarized as never-smokers (0 pack years) and ever-smokers (>0 pack years). Pathologic TNM staging was categorized as stage I versus stage II. For multivariate analysis, all variables were included that were moderately associated ( $P < 0.1$ ) with RFS or OS in any of the analyses.

### Bioinformatics

Associations of gene expression levels with prognosis of NSCLC patients in 7 other expression profile studies were obtained from the Prognoscan database (26). In the Prognoscan database, association of gene expression with survival of patients was evaluated by the minimum  $P$  value approach. Briefly, patients were first arranged by expression levels of a given gene. They were then divided into high- and low-expression groups at all possible cutoff points, and the risk differences of any 2 groups were estimated by the log-rank test. Finally, the cutoff point that gave the most pronounced  $P$  value was selected.

### Results

#### **EGFR/KRAS/ALK mutations and clinicopathologic characteristics of lung adenocarcinomas subjected to gene expression profiling**

Among 226 stages I and II lung adenocarcinomas, *EGFR* and *KRAS* mutations were mutually exclusively detected in 127 (56%) and 20 (9%) cases, respectively, and an *EML4-ALK* fusion gene was expressed in 11 (4.9%) cases (Table 1). *EGFR* or *KRAS* mutations were not detected in any of the 11 cases with *EML4-ALK* fusion expression; thus, the occurrence of *ALK* rearrange-

ments in a mutually exclusive manner with *EGFR* and *KRAS* mutations in lung adenocarcinoma was confirmed. The incidence and the fraction of *EGFR*-, *KRAS*-, and *ALK*-positive cases in this study were consistent with those in previous studies (5–7, 9, 13). Accordingly, the remaining 68 (30%) cases were defined as "triple-negative adenocarcinomas" because of the absence of *EGFR*, *KRAS*, and *ALK* mutations. Clinicopathologic features of *EGFR*-positive adenocarcinomas and *KRAS*-positive adenocarcinomas in this study are well consistent with those in previous studies of Japanese populations (27, 28). Patients with *ALK*-positive adenocarcinomas were younger and more likely to be never-smokers, as previously indicated (4, 6–8). Triple-negative adenocarcinomas showed similar clinicopathologic features to those of *KRAS*-positive adenocarcinomas, that is, a predominance of males, ever-smokers, and advanced stages.

#### **Expression profile unique to ALK-positive lung adenocarcinomas**

All 226 cases were subjected to genome-wide expression profiling using Affymetrix U133Plus2.0 arrays. One hundred and seventy-four genes, evaluated with 190 probes (Supplementary Table S1), were selected as those preferentially expressed in either *ALK*-positive adenocarcinomas or triple-negative adenocarcinomas under the criteria described in Materials and Methods. In particular, 10 genes evaluated with 11 probes were markedly upregulated according to the criteria of fold-differences more than 2.0 with  $P$  values less than 0.05 (Supplementary Table S2). It was noted that 2 probes for the *ALK* gene were present among them, and 1 of them (probe ID = 208212\_s\_at) showed the highest fold-difference of 8.7 between *ALK*-positive/triple-negative adenocarcinomas and *EGFR*-positive/*KRAS*-positive adenocarcinomas among the 190 probes. This result indicated that there is a subset of adenocarcinomas in which *ALK* was overexpressed. Therefore, an unsupervised

**Table 1.** Clinicopathologic characteristics of 226 lung adenocarcinomas subjected to expression profile analysis

Variable	Mutation				Expression profile		
	All	EGFR (+)	KRAS (+)	ALK (+)	Triple (–)	Group A	Group B
No. of cases	226	127	20	11	68	36	32
Age							
Mean	60	60	60	54	61	61	60
Range	30–76	35–72	46–75	30–68	46–76	46–71	47–76
Sex							
Male	105	50	12	2	41	25	16
Female	121	77	8	9	27	11	16
Smoking habit							
Never-smoker	115	67	10	7	31	10	21
Ever-smoker	111	60	10	4	37	26	11
pStage							
IA	114	77	6	3	28	10	18
IB	54	26	8	0	20	12	8
II	58	24	6	8	20	14	6

Table 2. Genes upregulated in *ALK*-positive lung adenocarcinomas

Gene symbol <sup>a</sup>	Gene name	Probe ID	Fold difference
<i>ALK</i>	Anaplastic lymphoma receptor tyrosine kinase	208212_s_at	55.2
<i>EST</i>	Transcribed locus	242964_at	26.8
<i>ALK</i>	Anaplastic lymphoma receptor tyrosine kinase	208211_s_at	17.2
<i>GRIN2A</i>	Glutamate receptor, ionotropic, <i>N</i> -methyl <i>D</i> -aspartate 2A	242286_at	13.0
<i>GRIN2A</i>	Glutamate receptor, ionotropic, <i>N</i> -methyl <i>D</i> -aspartate 2A	231384_at	12.4
<i>MUC5AC</i> /// <i>MUC5B</i>	Mucin 5AC, oligomeric mucus/gel-forming /// mucin 5B, oligomeric mucus/gel-forming	222268_x_at	9.2
<i>EST</i>	Transcribed locus	1570291_at	8.1
<i>LOC100292909</i>	Hypothetical protein LOC100292909	241535_at	7.7
<i>BLID</i>	BH3-like motif containing, cell death inducer	1555675_at	7.4
<i>LOC100130894</i>	Hypothetical LOC100130894	1564158_a_at	6.1
<i>CLDN10</i>	Claudin 10	1556687_a_at	6.0
<i>KRT16</i>	Keratin 16	209800_at	5.9
<i>PROM2</i>	Prominin 2	1562378_s_at	5.6
<i>GJB5</i>	Gap junction protein, beta 5, 31.1 kDa	206156_at	5.0
<i>KIAA1644</i>	KIAA1644	221901_at	4.8
<i>EPHB1</i>	EPH receptor B1	210753_s_at	4.5
<i>LRRC4</i>	Leucine rich repeat containing 4	223552_at	4.2
<i>EST</i>	Transcribed locus	235373_at	3.4
<i>tcag7.1188</i>	Hypothetical LOC340340	1561254_at	3.3
<i>SBNO2</i>	Strawberry notch homolog 2 ( <i>Drosophila</i> )	204166_at	3.3
<i>EST</i>	Transcribed locus	241083_at	3.1
<i>SLC25A37</i>	Solute carrier family 25, member 37	222528_s_at	3.1
<i>NDP</i>	Norrie disease (pseudoglioma)	206022_at	3.1
<i>EST</i>	Transcribed locus	243478_at	3.0
<i>EST</i>	Transcribed locus	239136_at	2.9
<i>RHOV</i>	ras homolog gene family, member V	241990_at	2.9
<i>YIF1B</i>	Yip1 interacting factor homolog B ( <i>S. cerevisiae</i> )	231211_s_at	2.9
<i>RPRM</i>	Reprimo, TP53 dependent G2 arrest mediator candidate	219370_at	2.5
<i>SYT12</i>	Synaptotagmin XII	228072_at	2.5
<i>HES2</i>	Hairy and enhancer of split 2 ( <i>Drosophila</i> )	231928_at	2.4
<i>CDH11</i>	Cadherin 11, type 2, OB-cadherin (osteoblast)	239769_at	2.2
<i>IRAK3</i>	Interleukin-1 receptor-associated kinase 3	220034_at	2.1

<sup>a</sup>Genes with fold difference >2.0 and *P* < 0.05 between *ALK*-positive and *ALK*-negative adenocarcinomas are shown.

hierarchical clustering using these 190 probes was done on 11 *ALK*-positive adenocarcinomas and 68 triple-negative adenocarcinomas (Supplementary Figs. S1 and S2). There were 3 distinct sets of genes/probes, as indicated by red, yellow, and blue bars on the left of the heat map. Two probes for the *ALK* gene were present in the gene/probe set with a yellow bar, and 11 cases with extremely high levels of *ALK* expression comprised a small subcluster in the right side of cluster 1. All the 11 cases corresponded to the ones with *EML4-ALK* fusion gene expression.

The results strongly indicated that *ALK*-positive adenocarcinomas have distinct expression profiles in comparison with *ALK*-negative adenocarcinomas, including not only triple-negative adenocarcinomas but also *EGFR*-positive and *KRAS*-positive adenocarcinomas. Therefore, genes with fold-differences more than 2.0 and *P* values less than 0.05 in their expression between *ALK*-positive adenocarcinomas and

*ALK*-negative adenocarcinomas were further selected from the 190 probes. Thirty genes with 32 probes were then selected (Table 2). The *ALK* gene showed the highest level of fold difference in *ALK*-positive adenocarcinomas. Therefore, as previously reported (29–31), *ALK*-positive adenocarcinomas express high levels of *ALK* gene products, supporting that upregulation of the *ALK* gene is a biological consequence of *ALK* rearrangements in lung adenocarcinoma cells. Expression profiling further revealed that various other genes are distinctly upregulated in *ALK*-positive adenocarcinomas. In particular, fold differences of *GRIN2A* (glutamate receptor, ionotropic, *N*-methyl *D*-aspartate 2A) expression were more than 10, as with *ALK* expression. Moreover, *GRIN2A* was branched most closely to *ALK* in the heat map (Supplementary Fig. S2). Therefore, high levels of *GRIN2A* expression can be a characteristic unique to *ALK*-positive adenocarcinomas, in addition to upregulation of the *ALK* gene itself. The levels of *GRIN2A* expression in *ALK*-




Figure 1. Unsupervised hierarchical clustering of 11 *ALK*-positive adenocarcinomas and 68 triple-negative adenocarcinomas. Triple-negative adenocarcinomas were separated into 36 group A cases and 32 group B cases, and group A cases construct cluster 1 with 11 *ALK*-positive adenocarcinoma cases. Clinical and genetic features are shown below the tree; sex (black, male; white, female); smoking status (black, ever-smoker; white, never-smoker); pathologic stage (black, stage II; gray, stage IB; white, stage IA); relapse (black, evidence of relapse; white, no evidence of relapse); *ALK* (yellow, *ALK*-fusion gene expression positive; white, negative). Three colored bars according to the main branches of probes/genes are shown on the left. Positions of probes for *ALK*, *GRIN2A*, and *DEPDC1* are shown on the right. ADC, adenocarcinoma.

positive adenocarcinomas were significantly higher than those in *ALK*-negative adenocarcinomas by quantitative RT-PCR analysis (Supplementary Fig. S3).


#### Triple-negative lung adenocarcinomas with poor prognosis identified by gene expression profiling

By the unsupervised hierarchical clustering, 68 triple-negative adenocarcinomas were separated into 2 major groups, one containing 36 cases and the other 32 cases, designated as groups A and B, respectively (Fig. 1). Group A comprised cluster 1 with 11 *ALK*-positive adenocarcinomas. Group A cases were dominant in males, ever-smokers, and advanced stages, whereas group B cases were dominant in never-smokers and early stages (Table 1), indicating that group A cases comprise an aggressive type in triple-negative adenocarcinomas. Therefore, we next compared RFS and OS among the 5 groups of patients; groups A and B, *EGFR*-positive cases, *KRAS*-positive cases, and *ALK*-positive cases (Fig. 2). Among the 226 cases, 204 cases that received complete resection and did not receive postoperative chemotherapy and/or radiotherapy were subjected to survival analysis. Group A cases ( $n = 32$ ) showed the worst prognosis

for both RFS and OS among the 5 groups (Fig. 2A and B). In particular, group A cases showed significantly worse prognosis ( $P < 0.05$ ) for both RFS and OS than group B cases ( $n = 30$ ) and *EGFR*-positive cases ( $n = 116$ ) by the log-rank test. Such differences were marginally significant between group A cases and *KRAS*-positive cases ( $n = 19$ ) and not significant between group A cases and *ALK*-positive cases ( $n = 7$ ), probably because the numbers of *KRAS*-positive and *ALK*-positive cases were smaller than those of group B and *EGFR*-positive cases.

Similar results were obtained from the analysis of 162 patients with stage I adenocarcinomas (Fig. 2C and D), indicating the independency of these associations with staging. Therefore, we next carried out multivariate analyses on RFS and OS of these 5 groups (Table 3). In the analysis of 204 stages I and II patients, RFS and OS of group A cases were significantly worse than those of *EGFR*-positive and group B cases, and the differences were independent of staging. HRs of *ALK*-positive and *KRAS*-positive cases were also as high as *EGFR*-positive and group B cases, although only the difference in RFS was statistically significant between group A cases and *KRAS*-positive cases. This could be also due to the small numbers

Figure 2. Kaplan–Meier survival curves for RFS and OS of 204 lung adenocarcinoma cases according to *EGFR*-positive, *KRAS*-positive, *ALK*-positive, group A, and group B. RFS and OS of stage I–II (A, B) and stage I (C, D) cases are shown.



of *KRAS*-positive and *ALK*-positive cases. Accordingly, multivariate analyses of 162 stage I patients further showed significant differences in RFS and OS between group A cases and *EGFR*-positive cases, and also between group A cases and group B cases. Because numbers of *KRAS*-positive cases and *ALK*-positive cases were small, we next compared RFS and OS between group A patients and patients in all 4 other groups combined ("Others" in Table 3). Differences in RFS as well as those in OS were highly significant and independent of staging. These results strongly indicated that group A patients comprise a distinct subclass of *EGFR*/*KRAS*/*ALK*-negative lung adenocarcinomas, and the prognoses of group A patients were the worst among the 5 groups of patients.

#### Clustering of lung adenocarcinomas with poor prognosis by gene expression profiling

We next carried out unsupervised hierarchical clustering of all the 226 adenocarcinoma cases, including 127 *EGFR*-positive cases and 20 *KRAS*-positive cases, to investigate whether expression profiling with a set of 174 genes with 190 probes could extract group A cases as a unique subset among all adenocarcinomas, and whether the profiling could be useful for prognosis prediction of patients with any genotypes of adenocarcinomas in general. As shown in Supplementary Fig. S4, clustering patterns of all the 226 patients were very similar to those of the 79 patients consisting of 11 *ALK*-positive cases and 68 triple-negative cases. In particular, the 11 *ALK*-positive cases comprised a small cluster in the right side of Cluster 1 (Cluster 1b), supporting that *ALK*-positive adenocarcinomas show unique expression profiles among all adenocarcinomas. Group A and group B cases also have a tendency to accumulate in Clusters 1a and Cluster 2, respectively. However, group A cases often comprise clusters with the *KRAS*-positive cases,

whereas group B cases were distributed with the *EGFR*-positive cases. Therefore, group A and group B triple-negative adenocarcinomas were not exclusive with the *EGFR*-positive and *KRAS*-positive adenocarcinomas by expression profiling of these 174 genes. Therefore, expression profiling with a set of the 174 genes was concluded to be useful to distinguish *ALK*-positive adenocarcinomas among all lung adenocarcinomas.

However, RFS of 119 patients in Cluster 1 was significantly worse than RFS of 85 patients in Cluster 2 (HR = 3.73,  $P = 0.00016$ ). When Cluster 1 was further divided into 2 subclasses 1a and 1b of the right and left sides, respectively, Cluster 1a containing most of group A patients showed the worst prognosis among the 3 subclasses (Supplementary Fig. S4). Therefore, the expression signature of these 174 genes was indicated to be useful for prognostic prediction of adenocarcinoma patients, in particular of triple-negative adenocarcinoma patients.

#### Minimum set of genes characterizing triple-negative lung adenocarcinomas with poor prognosis

The above results implied that triple-negative adenocarcinomas can be classified into 2 distinct subgroups by expression profiling and prognoses of these 2 groups are significantly different from each other. Accordingly, expression of several genes among the 174 genes was expected to be independently associated with prognosis of triple-negative adenocarcinoma patients. Therefore, we next selected genes whose expression was associated with prognosis from the 174 genes evaluated by the 190 probes. To evaluate the prognostic value of each probe and to make a comparative study for association of gene expression with prognosis in other cohorts possible, we took a minimum  $P$  value approach for grouping the patients for survival analysis because of the following reason. A database

Table 3. Hazard ratios for relapse-free and overall survivals in lung adenocarcinomas

Survival	Case (n)	Variable	Univariate		Multivariate	
			HR (95% CI)	P	HR (95% CI)	P
Relapse free	Stage I-II (204)	Age	1.03 (0.99–1.07)	0.12	1.04 (0.99–1.08)	0.092
		Sex (male/female)	1.39 (0.82–2.38)	0.22	1.00 (0.49–2.05)	0.99
		Smoking habit (ever/never)	1.43 (0.84–2.44)	0.19	1.10 (0.54–2.24)	0.80
		pStage (II/I)	1.86 (1.41–2.45)	1.3E-05	3.50 (1.93–6.34)	3.6E-05
		Subgroup				
		Group A/ALK (+)	4.78 (0.63–35.99)	0.13	6.01 (0.76–47.82)	0.09
		Group A/KRAS (+)	2.43 (0.96–6.17)	0.062	2.85 (1.10–7.35)	0.031
		Group A/EGFR (+)	3.58 (1.93–6.64)	5.3E-05	2.76 (1.44–5.29)	0.0022
		Group A/Group B	4.58 (1.69–12.42)	0.0028	4.10 (1.50–11.24)	0.0061
		Group A/Others	3.56 (2.00–6.34)	1.6E-05	3.04 (1.68–5.53)	2.5E-04
	Stage I (162)	Age	1.01 (0.96–1.06)	0.69	1.00 (0.95–1.05)	0.97
		Sex (male/female)	0.99 (0.50–1.96)	0.98	0.83 (0.33–2.07)	0.69
		Smoking habit (ever/never)	1.06 (0.54–2.08)	0.87	0.97 (0.39–2.45)	0.95
		Subgroup				
		Group A/ALK (+)	—	—	—	—
		Group A/KRAS (+)	2.31 (0.73–7.28)	0.15	2.36 (0.73–7.62)	0.15
		Group A/EGFR (+)	4.33 (2.00–9.35)	2.0E-04	4.51 (2.05–9.91)	1.7E-04
		Group A/Group B	5.36 (1.49–19.24)	0.010	5.52 (1.50–20.37)	0.010
		Group A/Others	4.18 (2.03–8.60)	1.0E-04	4.32 (2.06–9.09)	1.1E-04
		Overall	Stage I-II (204)	Age	1.03 (0.98–1.08)	0.33
Sex (male/female)	1.69 (0.82–3.48)			0.16	0.89 (0.33–2.41)	0.82
Smoking habit (ever/never)	1.91 (0.92–3.97)			0.084	1.46 (0.54–3.92)	0.45
pStage (II/I)	2.07 (1.45–2.97)			7.2E-05	3.93 (1.83–8.44)	4.6E-04
Subgroup						
Group A/ALK (+)	2.95 (0.38–22.78)			0.30	3.50 (0.41–29.85)	0.25
Group A/KRAS (+)	3.12 (0.88–11.09)			0.079	3.31 (0.91–12.03)	0.069
Group A/EGFR (+)	4.59 (2.06–10.23)			2.0E-04	3.35 (1.44–7.81)	0.005
Group A/Group B	6.83 (1.53–30.54)			0.012	5.68 (1.24–25.95)	0.025
Group A/Others	4.50 (2.17–9.36)			5.7E-05	3.61 (1.68–7.78)	0.0010
Stage I (162)	Age		0.99 (0.93–1.06)	0.73	0.98 (0.91–1.04)	0.45
	Sex (male/female)		1.15 (0.43–3.08)	0.79	0.77 (0.20–3.00)	0.70
	Smoking habit (ever/never)		1.47 (0.55–3.91)	0.45	1.26 (0.32–4.89)	0.74
	Subgroup					
	Group A/ALK (+)		—	—	—	—
	Group A/KRAS (+)		5.79 (0.71–47.3)	0.10	5.61 (0.67–46.84)	0.11
	Group A/EGFR (+)		5.83 (2.04–16.71)	0.0010	6.06 (2.08–17.71)	9.8E-04
	Group A/Group B		9.13 (1.12–74.34)	0.039	9.32 (1.10–78.61)	0.040
	Group A/Others		6.30 (2.34–16.99)	2.8E-04	6.47 (2.33–17.98)	3.4E-04

named PrognScan was recently developed by coauthors of this study (26). In the PrognScan database, minimum *P* values for the association of gene expression with prognosis of all probes in a platform are available for a number of cohorts that have been published. Therefore, it was possible to validate the present findings using data from various other cohorts by the same criteria. According to the method described previously (26), corrected minimum *P* values were calculated for each probe to control the error rate for the evaluation of the association with RFS and OS. Expression of 11 genes evaluated with 12 probes (2 probes for the *DEPDC1* gene) showed

significant associations with both RFS and OS in 62 triple-negative adenocarcinomas and also in 46 stage I triple-negative adenocarcinomas (Table 4). Among the 11 genes, expression of 10 genes was positively correlated with poor prognosis, whereas that of the remaining 1 gene, *KIF19*, expression was negatively correlated with poor prognosis.

We first selected 174 genes as being preferentially expressed in either *ALK*-positive adenocarcinomas or triple-negative adenocarcinomas by the criteria of "probes whose expression levels in any adenocarcinomas with *EGFR* or *KRAS* mutations were lower than the mean expression

Table 4. List of genes whose expression is associated with relapse free survival and overall survival of patients with lung adenocarcinoma

Dataset	Gene symbol	Probe ID (for NCC)	NCC																CAN/DF		HLM		MSK		UM		Nagoya		Duke		Seoul	
			TN, Stage I-II				TN, Stage I				All Stage I-II				All Stage I				Stage I-II		Stage I-III		Stage I-III		Stage I-III		Stage I-III					
			RFS		OS		RFS		OS		RFS		OS		RFS		OS		OS	OS	OS	OS	OS	OS	RFS	RFS						
			n = 62	n = 62	n = 46	n = 46	n = 204	n = 204	n = 162	n = 162	n = 82	n = 79	n = 104	n = 178	n = 117	n = 111	n = 138															
	P	HR	P	HR	P	HR	P	HR	P	HR	P	HR	P	HR	P	HR	P	HR	P	HR	P	HR	P	HR	P	HR	P	HR				
DEPDC1	222958_s_at	0.00	2.3	0.00	3.0	0.00	3.0	0.02	2.7	0.00	2.1	0.00	1.8	0.00	2.0	0.00	2.1	—	—	—	—	0.03	1.1	—	—	0.00	1.6	0.04	1.0	0.01	0.9	
DEPDC1	235545_at	0.00	1.8	0.01	2.3	0.00	2.4	0.04	2.6	0.00	1.4	0.00	1.6	0.00	1.3	0.00	2.2	—	—	—	—	0.03	1.1	—	—	0.00	1.6	0.04	1.0	0.01	0.9	
FOSL2	218881_s_at	0.01	1.7	0.03	1.7	0.02	1.8	0.00	3.3	0.00	1.2	0.00	1.7	0.00	1.4	0.00	2.4	—	—	0.00	1.7	—	—	0.02	0.7	—	—	—	—	0.01	1.0	
MCM4	222037_at	0.00	1.8	0.00	3.0	0.01	2.0	0.04	2.6	0.00	1.4	0.00	1.8	0.00	1.5	0.00	2.1	—	—	—	—	—	—	—	0.00	1.7	—	—	—	—	—	
UBE2S	202779_s_at	0.00	3.0	0.02	16.0	0.01	2.8	0.02	16.6	0.00	1.6	0.02	1.4	0.00	1.6	0.00	2.1	—	—	—	—	0.05	1.0	—	—	—	—	—	—	—	—	
CD300A	217078_s_at	0.01	1.7	0.00	2.1	0.04	1.7	0.00	2.8	0.00	1.1	0.00	1.5	0.01	1.2	0.01	1.7	—	—	—	—	0.00	1.5	—	—	—	—	—	—	—	—	
SLITRK4	232636_at	0.02	1.7	0.03	1.7	0.00	2.9	0.00	2.5	0.01	1.1	0.00	1.4	0.04	1.1	0.00	2.0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
KRT16	209800_at	0.00	2.0	0.00	2.5	0.00	2.4	0.00	2.7	0.00	1.2	0.00	1.4	0.01	1.2	0.01	1.7	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
SIGLEC9	210569_s_at	0.00	1.9	0.01	2.0	0.00	2.1	0.04	2.1	0.00	1.6	0.00	1.4	0.00	1.7	0.00	2.2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
DIAPH3	232596_at	0.02	1.5	0.00	3.0	0.05	1.6	0.03	2.6	0.00	1.2	0.00	2.1	0.00	1.5	0.00	2.0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
LOC152225	1562048_at	0.01	1.5	0.00	2.3	0.02	1.7	0.00	2.7	0.00	1.3	0.00	1.9	—	—	0.00	1.9	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
KIF19	1553314_a_at	0.01	-1.5	0.05	-1.6	0.00	-3.0	0.00	-2.5	—	—	0.03	-1.4	—	—	—	—	—	—	—	—	—	—	—	0.00	-1.4	—	—	—	—	—	

Abbreviations: NCC, National Cancer Center; TN, Triple-negative.  
HRs (log2 ratio) with corrected P value < 0.05 are shown.






Figure 3. Unsupervised hierarchical clustering based on the expression of a set of 9 genes. All 204 stage I-II adenocarcinomas and 62 triple-negative (TN) stage I-II adenocarcinomas of the National Cancer Center (NCC) data set subjected to survival analysis were analyzed, and a cluster with higher expression of these genes than the other cluster was recognized as a high-risk group (red bar). Results of 117 adenocarcinomas, including 57 double-negative (DN) adenocarcinomas, of the Aichi Cancer Center (ACC) data set are shown below.

level of a total of 54,675 probes." Then, 11 of the 174 genes were further selected as being associated with prognosis of patients with triple-negative adenocarcinomas. Therefore, higher expression of several genes among the 11 genes was predicted to be associated with poorer prognosis, even when all adenocarcinoma cases, including *EGFR*-positive, *KRAS*-positive, and *ALK*-positive adenocarcinomas were analyzed together. Furthermore, triple-negative adenocarcinomas with poor prognosis would be separated into a high-risk group classified with this procedure. For this reason, we next analyzed all 204 adenocarcinoma cases. Among the 11 genes with 12 probes, 9 genes with 10 probes showed significant associations with both RFS and OS in all 204 adenocarcinoma cases and also in 162 stage I adenocarcinoma cases. *LOC152225* and *KIF19* were excluded because of no significant associations in stage I adenocarcinoma cases. As predicted, higher expression of the 9 genes was correlated with poorer prognosis in the analysis of RFS and OS among 204 stages I and II cases and also among 162 stage I cases.

The result strongly indicated that unsupervised hierarchical clustering using this 10 probe set (9 genes) would separate the patients into high-risk and low-risk groups for prognosis and that all group A triple-negative adenocarcinoma patients with poor prognosis would be classified into the high-risk group (Fig. 3 and Supplementary Table S3). As expected, expression profiling of these 9 genes successfully separated the 204

patients into high-risk and low-risk groups with significantly different RFS (HR = 3.79, 95% CI = 2.19–6.55,  $P = 1.9E-06$ ) as well as OS (HR = 5.72, 95% CI = 2.53–12.87,  $P = 2.5E-05$ ). Furthermore, if 62 triple-negative cases only were separated with these 9 genes, HRs for both RFS and OS were much higher than those with separation of all the 204 cases. All the relapsed cases in group A were separated into the high-risk group in the analyses of both cases (all the 204 cases and the 62 triple-negative cases only), supporting that triple-negative adenocarcinoma cases with poor prognosis can be selected as a high-risk group from all the adenocarcinoma cases by expression profiling of these 9 genes (Fig. 3). This profiling further separated 162 stage I cases as well as 46 stage I triple-negative adenocarcinoma cases into high-risk and low-risk groups with significantly different RFS as well as OS (Supplementary Fig. S5 and Supplementary Table S3). Again, HRs for both RFS and OS were much higher in triple-negative adenocarcinoma cases than in all adenocarcinoma cases. Accordingly, high levels of expression in these 9 genes were concluded to be distinct characteristics of triple-negative adenocarcinomas with poor prognosis.

#### Validation of associations using independent expression profiling data

To validate the present findings using the data of other cohorts, we searched for expression profiling data with

mutation data of the *EGFR*, *KRAS*, and *ALK* genes in various databases. However, there has been no cohort in which expression profiles specifically in triple-negative adenocarcinomas were analyzed. Therefore, unsupervised hierarchical clustering using these 9 genes was done on a cohort of 117 Japanese lung adenocarcinoma cases because expression profile data as well as *EGFR/KRAS* mutation data were available only in this cohort (32). This study included 57 adenocarcinoma cases without *EGFR* and *KRAS* mutations. Although a different array platform was used, the data for all the 9 genes were available for clustering. These cases were separated into 2 groups of 33 cases and 24 cases (Fig. 3). OS of the 33 cases was significantly shorter than that of the 24 cases (HR = 3.17, 95% CI = 1.17–8.63,  $P = 2.4E-02$ ; Supplementary Table S3). As with our cohort, the high-risk group showed a significantly higher HR of 2.73, even when all the 117 cases were analyzed together. Although *ALK* mutation data were not available for this cohort, the results strongly supported that expression profiling of the 9 genes would be highly informative for prediction of prognosis of lung adenocarcinoma patients, in particular patients with *EGFR*- and *KRAS*-negative adenocarcinomas.

#### Associations of *DEPDC1* expression with prognosis of NSCLC patients

Associations of gene expression with prognosis in various cancers are available from the Prognoscan database (22). Therefore, associations of expression of these 9 genes with prognosis of NSCLC patients were examined in 7 other cohorts (Table 4). Notably, *DEPDC1* expression was positively associated with poor prognosis in 4 of the 7 cohorts; MSK, Nagoya, Duke, and Seoul. The results strongly indicated that *DEPDC1* expression can be a novel prognostic marker for patients with NSCLC. Representative data showing the association of *DEPDC1* expression with prognosis in 204 adenocarcinoma patients obtained from the minimum  $P$  value approach are shown in Supplementary Fig. S6. Associations of *DEPDC1* expression with RFS and OS were validated by quantitative RT-PCR analysis of 204 stages I and II cases and also of 162 stage I cases (Supplementary Fig. S3).

*FOSL2* expression was associated with prognosis in 3 of the 7 cohorts, whereas *MCM4*, *CD300A*, and *UBE2S* expression was associated in 1 cohort, respectively (Table 4).

#### Discussion

In this study, we attempted to characterize *ALK*-positive adenocarcinomas and triple-negative adenocarcinomas by genome-wide expression profiling. For this purpose, we selected a set of genes that are not transcriptionally activated in any *EGFR*-positive and *KRAS*-positive adenocarcinomas, and obtained 2 pieces of unique evidence. One is that *ALK*-positive adenocarcinomas show unique expression profiles in comparison with any other types of adenocarcinomas. The other is that there is a group of patients with extremely poor prognosis among triple-negative adenocarcinomas. This group, herein designated as group A, of patients showed much worse prognoses than patients with *EGFR*, *KRAS*, or *ALK* mutations and

also than the other group, group B, of patients with triple-negative adenocarcinomas.

*ALK*-positive adenocarcinomas are sensitive to *ALK* TKIs with an overall response rate of 55% (8). Therefore, for the clinical application of *ALK*-targeted therapy, it is indispensable to develop a simple and reliable method for detection of *ALK* rearrangements in lung adenocarcinomas. Here, we showed that *ALK* expression is exclusively high only in *ALK*-positive adenocarcinomas and that several other genes, including *GRIN2A*, are overexpressed together with *ALK* specifically in *ALK*-positive adenocarcinomas. Therefore, *GRIN2A* can be a biomarker for detection of *ALK*-positive adenocarcinomas. *GRIN2A* encodes an *N*-methyl-D-aspartate (NMDA) receptor, which is a neurotransmitter-gated ion channel involved in regulation of synaptic function in the central nervous system (33). It was noted that the *GRIN2A* gene was recently reported to be frequently mutated in melanoma (34). Therefore, although the biological significance of *GRIN2A* upregulation in *ALK*-positive adenocarcinomas remains unclear, *GRIN2A* expression may play some important role in the phenotype unique to *ALK*-positive adenocarcinomas. Expression profiles unique to *ALK*-positive adenocarcinomas, shown here, will be also informative to improve clinical detection of *ALK* rearrangements.

Group A cases were discriminated by expression profiling of 9 genes among stage I–II cases who received complete surgical resection of tumors. Therefore, this gene set will be applicable as biomarkers to select lung adenocarcinoma patients who will benefit from adjuvant therapy after surgery, in particular to select them among patients with triple-negative adenocarcinomas. For this reason, combined analyses of this expression profiling with mutational analyses of the *EGFR*, *KRAS*, and *ALK* genes will be appropriate to pick out triple-negative adenocarcinoma patients with poor prognosis from all the adenocarcinoma patients. Molecular targeting drugs against triple-negative adenocarcinomas are not available at present; therefore, genes upregulated in group A cases will also be applicable as targets for therapy. *DEPDC1* was previously identified as being upregulated in bladder cancer and breast cancer (35–37). Because *DEPDC1* expression was hardly detectable in any normal tissues except testis, it has been considered as a cancer/testis antigen and also as a promising target of therapeutic drugs (35, 36). This study showed that *DEPDC1* is preferentially expressed in triple-negative adenocarcinomas with poor prognosis. In the Prognoscan database, *DEPDC1* expression is shown to be positively associated with poor prognosis in bladder cancer, multiple myeloma, breast cancer, glioma, and melanoma. Therefore, *DEPDC1* could be a novel target for diagnosis as well as therapy in various cancers, including lung adenocarcinoma.

Identification of genetic alterations that occur specifically in group A cases will be also of great importance for the development of target therapy for stages I and II lung adenocarcinoma patients with poor outcomes. Group A cases include males and ever-smokers as a majority (Table 1); therefore, group A cases were likely to carry several genetic alterations induced by tobacco carcinogens leading to poor outcomes. Identification of genetic alterations in

group A adenocarcinomas will further facilitate the development of targeted therapies for lung adenocarcinomas with poor prognosis.

#### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

#### Acknowledgments

The authors thank Dr. Teruhiko Yoshida and Ms. Sachiyo Mimaki for their efforts in expression profiling.

#### Grant Support

This work was supported in part by grants-in-aid from the Ministry of Health, Labor and Welfare for the 3rd-term Comprehensive 10-year Strategy for Cancer Control and from the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO: 10-41). K. Shiraiishi was an awardee of a Research Resident Fellowship from the Foundation for Promotion of Cancer Research in Japan.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 23, 2011; revised October 19, 2011; accepted October 21, 2011; published OnlineFirst November 11, 2011.

#### References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010;127:2893-917.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005;55:74-108.
3. Colvy T, Noguchi M, Henschke C, Vazquez M, Geisinger K, Yokose T, et al. Adenocarcinoma. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World Health Organization classification of tumors: pathology and genetics: tumours of the lung, pleura, thymus and heart. IARC Press: Lyon, France; 2004. p. 35-44.
4. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. *Lancet Oncol* 2011;12:175-80.
5. Herbst RS, Heymach JV, Lippman SM: Lung cancer. *N Engl J Med* 2008;359:1367-80.
6. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer—is it becoming a reality? *Nat Rev Clin Oncol* 2010;7:401-14.
7. Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Fiorella C, et al. 2288; Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. *Cancer Treat Rev* 2010;36 Suppl 3:S21-9.
8. Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. *Cancer Cell* 2010;18:548-51.
9. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers—a different disease. *Nat Rev Cancer* 2007;7:778-90.
10. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. *N Engl J Med* 2009;361:958-67.
11. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009;361:947-57.
12. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. *Nat Rev Drug Discov* 2007;6:541-55.
13. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 2007;448:561-6.
14. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. *J Clin Oncol* 2006;24:1679-88.
15. Angulo B, Suarez-Gauthier A, Lopez-Rios F, Medina PP, Conde E, Tang M, et al. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. *J Pathol* 2008;214:347-56.
16. Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. *Am J Surg Pathol* 2008;32:810-27.
17. Meyerson M, Carbone D. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. *J Clin Oncol* 2005;23:3219-26.
18. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World Health Organization classification of tumors: pathology and genetics: tumours of the lung, pleura, thymus and heart. IARC Press: Lyon, France; 2004. p. 1-344.
19. Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. *Clin Cancer Res* 2011;17:1875-82.
20. Robins JM, Gail MH, Lubin JH. More on "Biased selection of controls for case-control analyses of cohort studies". *Biometrics* 1986;42:293-9.
21. Richardson DB. An incidence density sampling program for nested case-control analyses. *Occup Environ Med* 2004;61:e59.
22. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci USA* 1998;95:14863-8. Available from: <http://rana.lbl.gov/eisen/>.
23. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. *J Clin Oncol* 2005;23:6829-37.
24. Takano T, Ohe Y, Tsuta K, Fukui T, Sakamoto H, Yoshida T, et al. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. *Clin Cancer Res* 2007;13:5385-90.
25. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. *Clin Cancer Res* 2008;14:6618-24.
26. Mizuno H, Kitada K, Nakai K, Sarai A. 2288; PrognoScan: a new database for meta-analysis of the prognostic value of genes. 2288; BMC Med Genomics 2009;2:18. Available from: <http://gibk21.bio.kyutech.ac.jp/PrognoScan/index.html>.
27. Mitsudomi T. Advances in target therapy for lung cancer. *Jpn J Clin Oncol* 2010;40:101-6.
28. Suda K, Tomizawa K, Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. *Cancer Metastasis Rev* 2010;29:49-60.
29. Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. *Mol Cancer* 2010;9:188.
30. Boland JM, Erdogan S, Vasmataz G, Yang P, Tillmans LS, Johnson MR, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. *Hum Pathol* 2009;40:1152-8.
31. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. *Clin Cancer Res* 2010;16:1561-71.

32. Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, Mitsudomi T, et al. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. *J Clin Oncol* 2009;27:2793-9.
33. Endele S, Rosenberger G, Geider K, Popp B, Tamer C, Stefanova I, et al. Mutations in *GRIN2A* and *GRIN2B* encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. *Nat Genet* 2010;42:1021-6.
34. Wei X, Walla V, Lin JC, Teer JK, Prickett TD, Gartner J, et al. Exome sequencing identifies *GRIN2A* as frequently mutated in melanoma. *Nat Genet* 2011;43:442-6.
35. Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, et al. Involvement of upregulation of *DEPDC1* (DEP domain containing 1) in bladder carcinogenesis. *Oncogene* 2007;26:6448-55.
36. Harada Y, Kanehira M, Fujisawa Y, Takata R, Shuin T, Miki T, et al. Cell-permeable peptide *DEPDC1-ZNF224* interferes with transcriptional repression and oncogenicity in bladder cancer cells. *Cancer Res* 2010;70:5829-39.
37. Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schiag PM, Kemmner W. Identification of early molecular markers for breast cancer. *Mol Cancer* 2011;10:15.